Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 323-336

  Toller, W ^a   Heringlake, M ^b   Guarracino, F ^c   Algotsson, L ^d   Alvarez, J ^e   Argyriadou, H ^f   Ben Gal, T ^g   Cerny V ^h   Cholley, B ^i,j   Eremenko, A ^k   Guerrero Orriach, J L ^l   Jarvela K ^m   Karanovic, N ⁿ   Kivikko, M ^o   Lahtinen, P ^p   Lomivorotov, V ^q   Mehta, R H ^r   Music S ^s   Pollesello, P ^o   Rex, S ^t   Riha, H ^u   Rudiger, A ^v   Salmenpera M ^w   Szudi, L ^x   Tritapepe, L ^y   Wyncoll, D ^z   Owall A ^aa   more..

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e Instituto de Salud Carlos III   (Spain)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g RABIN MEDICAL CENTER   (Israel)

^h UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k PETROVSKY NATIONAL RESEARCH CENTER OF SURGERY   (Russian Federation)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^m TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁿ UNIVERSITY HOSPITAL SPLIT   (Croatia)

^o ORION CORPORATION   (Finland)

^p KUOPIO UNIVERSITY HOSPITAL   (Finland)

^q MESHALKIN NATIONAL MEDICAL RESEARCH CENTER   (Russian Federation)

^r DUKE UNIVERSITY MEDICAL CENTER   (United States)

^s UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^t UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^u INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^v UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^w HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^x National Institute of Cardiology Budapest   (Hungary)

^y SAPIENZA UNIVERSITY OF ROME   (Italy)

^z ST THOMAS HOSPITAL   (United Kingdom)

^aa KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

CABG; Cardiac surgery; Cardioprotective; Inodilator; Low cardiac output syndrome; Valve surgery

Indexed keywords

LEVOSIMENDAN; MILRINONE; PLACEBO; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

AORTA VALVE REPLACEMENT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; HEART FAILURE; HEART OUTPUT; HEART PROTECTION; HEART SURGERY; HEART VALVE SURGERY; HUMAN; KIDNEY BLOOD FLOW; LOADING DRUG DOSE; MITRAL VALVE SURGERY; NONHUMAN; OFF PUMP CORONARY SURGERY; PERIOPERATIVE PERIOD; PORTAL VEIN BLOOD FLOW; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); EUROPE; PROCEDURES;

CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; HYDRAZONES; PERIOPERATIVE CARE; PREOPERATIVE CARE; PYRIDAZINES;

EID: 84930763870     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.02.022     Document Type: Review

References (71)

1. I. Ahmed, C.M. House, W.B. Nelson, Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB), J. Cardiothorac. Surg. 4 (2009) 24.
2. A. Rudiger, F. Businger, M. Streit, E.R. Schmid, M.Maggiorini, F. Follath, Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure, Swiss Med. Wkly. 139 (2009) 110-116.
3. V. Rao, J. Ivanov, R.D.Weisel, J.S. Ikonomidis, G.T. Christiakis, T.E. David, Predictors of low cardiac output syndrome after coronary artery bypass, J. Thorac. Cardiovasc. Surg. 112 (1996) 38-51.
4. T. Açil, R. Türköz, M. Açil, et al., Value of prolonged QRS duration as a predictor of low cardiac output syndrome in patients with impaired left ventricular systolic function who undergo isolated coronary artery bypass grafting, Am. J. Cardiol. 98 (2006) 1357-1362.
5. C.E. Hobson, S. Yavas, M.S. Segal, et al., Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery, Circulation 119 (2009) 2444-2453.
6. C. Ronco, M. Haapio, A.A. House, N. Anavekar, R. Bellomo, Cardiorenal syndrome, J. Am. Coll. Cardiol. 52 (2008) 1527-1539.
7. D.V. Nielsen, M.K. Hansen, S.P. Johnsen, M. Hansen, K. Hindsholm, C.H.J. Jakobsen, Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score matched analysis, Anesthesiology 120 (2014) 1098-1108.
8. Z. Papp, I. Édes, S. Fruhwald, et al., Levosimendan:molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan, Int. J. Cardiol. 159 (2012) 82-87.
9. O. Eriksson, P. Pollesello, H. Haikala, Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion, J. Cardiovasc. Pharmacol. 44 (2004) 316-321.
10. I. Lepran, P. Pollesello, S. Vajda, A. Varró, J.G. Papp, Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model, J. Cardiovasc. Pharmacol. 48 (2006) 148-152.
11. E.F. du Toit, A. Genis, L.H. Opie, P. Pollesello, A. Lochner, A role for the RISK pathway and KATP channels in pre- And post-conditioning induced by levosimendan in the isolated guinea-pig heart, Br. J. Pharmacol. 154 (2008) 41-50.
12. I.N. Jamali, J.R. Kersten, P.S. Pagel, D.A. Hettrick, D.C. Warltier, Intracoronary levosimendan enhances contractile function of stunned myocardium, Anesth. Analg. 85 (1997) 23-29.
13. J. Levijoki, P. Pollesello, P. Kaheinen, H. Haikala, Improved survival with simendan after experimental myocardial infarction in rats, Eur. J. Pharmacol. 419 (2001) 243-248.
14. R.W. Harrison, V. Hasselblad, R.H. Mehta, R. Levin, R.A. Harrington, J.H. Alexander, Effect of levosimendan on survival and adverse events after cardiac surgery: A meta-analysis, J. Cardiothorac. Vasc. Anesth. 27 (2013) 1224-1232.
15. L.V. Zingman, A.E. Alekseev, D.M. Hodgson-Zingman, A. Terzic, ATP-sensitive potassium channels: metabolic sensing and cardioprotection, J. Appl. Physiol. 103 (2007) 1888-1893.
16. J.D.McCully, S. Levitsky, Mitochondrial ATP-sensitive potassiumchannels in surgical cardioprotection, Arch. Biochem. Biophys. 420 (2003) 237-245.
17. J.G. Papp, P. Pollesello, A.F. Varró, A.S. Végh, Effect of levosimendan andmilrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs, J. Cardiovasc. Pharmacol. Ther. 11 (2006) 129-135.
18. C. Metzsch, Q. Liao, S. Steen, L. Algotsson, Levosimendan cardioprotection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model, Acta Anaesthesiol. Scand. 51 (2007) 86-93.
19. J.R.Kersten, M.W.Montgomery, P.S. Pagel, D.C.Warltier, Levosimendan, anewpositive inotropic drug, decreasesmyocardial infarct size via activation of KATP channels, Anesth. Analg. 90 (2000) 5-11.
20. P.G. Camici, S.K. Prasad, O.E. Rimoldi, Stunning, hibernation, and assessment of myocardial viability, Circulation 117 (2008) 103-114.
21. S. Sonntag, S. Sundberg, L.A. Lehtonen, F.X. Kleber, The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia, J. Am. Coll. Cardiol. 43 (2004) 2177-2182.
22. X. Wu, J. Wu, X. Yan, Y. Zhang, Enhancement of myocardial function and reduction of injury with levosimendan after percutaneous coronary intervention for acute myocardial infarction: A pilot study, Cardiology 128 (2014) 202-208.
23. T. Husebye, J. Eritsland, C. Müller, et al., Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: A randomized, placebo-controlled study, Eur. J. Heart Fail. 15 (2013) 565-572.
24. M.Hein, A.B. Roehl, J.H. Baumert, K. Scherer, P. Steendijk, R. Rossaint, Anti-ischemic effects of inotropic agents in experimental right ventricular infarction, Acta Anaesthesiol. Scand. 53 (2009) 941-948.
25. M. Kivikko, S. Antila, J. Eha, L. Lehtonen, P.J. Pentikäinen, Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure, Int. J. Clin. Pharmacol. Ther. 40 (2002) 465-471.
26. J. Lilleberg, M. Laine, T. Palkama, M. Kivikko, O. Pohjanjousi, M. Kupari, Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure, Eur. J. Heart Fail. 9 (2007) 75-82.
27. H.I. Eriksson, J.R. Jalonen, L.O. Heikkinen, et al., Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function, Ann. Thorac. Surg. 87 (2009) 448-454.
28. S.G. De Hert, S. Lorsomradee, S. Cromheecke, P.J. Van der Linden, The effects of levosimendan in cardiac surgery patients with poor left ventricular function, Anesth. Analg. 104 (2007) 766-773.
29. L. Tritapepe, C. De Santis, D. Vitale, et al., Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery, Br. J. Anaesth. 102 (2009) 198-204.
30. R. Levin, M. Degrange, C. Del Mazo, E. Tanus, R. Porcile, Preoperative levosimendan decreasesmortality and the development of lowcardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass, Exp. Clin. Cardiol. 17 (2012) 125-130.
31. H. Leppikangas, K. Järvelä, T. Sisto, et al., Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery, Br. J. Anaesth. 106 (2011) 298-304.
32. J. Lilleberg, M.S. Nieminen, J. Akkila, et al., Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting, Eur. Heart J. 19 (1998) 660-668.
33. R.L. Levin, M.A. Degrange, R. Porcile, et al., The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative lowcardiac output syndrome, Rev. Esp. Cardiol. 61 (2008) 471-479.
34. P. Lahtinen, O. Pitkänen, P. Pölönen, A. Turpeinen, V. Kiviniemi, A. Uusaro, Levosimendan reduces heart failure after cardiac surgery-a prospective, randomised, placebo-controlled trial, Crit. Care Med. 39 (2011) 2263-2270.
35. K. Järvelä, P. Maaranen, T. Sisto, E. Ruokonen, Levosimendan in aortic valve surgery: cardiac performance and recovery, J. Cardiothorac. Vasc. Anesth. 22 (2008) 693-698.
36. K. Jörgensen, O. Bech-Hanssen, E. Houltz, S.-E. Ricksten, Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis, Circulation 117 (2008) 1075-1081.
37. L. Severi, A. Lappa, G. Landoni, et al., Levosimendan versus intra-aortic balloon pump in high-risk cardiac surgery patients, J. Cardiothorac. Vasc. Anesth. 25 (2011) 632-636.
38. R. Gandham, A. Syamasundar, H. Ravulapalli, et al., A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair/replacement for severe mitral stenosis, Ann. Card. Anaesth. 16 (2013) 11-15.
39. S. Barisin, I.Husedzinovic, Z. Sonicki, N. Bradic, A. Barisin, D. Tonkovic, Levosimendan in off-pump coronary artery bypass: A four-times masked controlled study, J. Cardiovasc. Pharmacol. 44 (2004) 703-708.
40. I. Husedzinović, S. Barisin, N. Bradić, A. Barisin, Z. Sonicki, R. Milanović, Levosimendan as a new strategy during off-pump coronary artery bypass grafting: double-blind, randomised, placebo-controlled trial, Croat. Med. J. 46 (2005) 950-956.
41. R.K. Kodalli, A.S. Sundar, M. Vakamudi, et al., Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: A randomised controlled study, Ann. Card. Anaesth. 16 (2013) 94-99.
42. B. Shah, P. Sharma, A. Brahmbhatt, et al., Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: A double-blind randomised study, Indian J. Pharmacol. 46 (2014) 29-34.
43. G. Bragadottir, B. Redfors, S.-E. Ricksten, Effects of levosimendan on glomerular filtration rate, renal blood low, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: A randomised placebo-controlled study, Crit. Care Med. 41 (2013) 2328-2335.
44. A. Baysal, M. Yanartas, M. Dogukan, N. Gundogus, T. Kocak, C. Koksal, Levosimendan improves renal outcome in cardiac surgery: A randomised trial, J. Cardiothorac. Vasc. Anesth. 28 (2014) 586-594.
45. M.B. Yilmaz, E. Grossini, J.C. Silva Cardoso, et al., Renal effects of levosimendan: A consensus report, Cardiovasc. Drugs Ther. 27 (2013) 581-590.
46. J. Alvarez, A. Baluja, S. Selas, et al., A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: A randomised controlled study, Anaesth. Intensive Care 41 (2013) 719-727.
47. M.S. Nieminen, S. Fruhwald, L.M. Heunks, et al., Levosimendan: current data, clinical use, and future development, Heart Lung Vessel 5 (2013) 227-245.
48. S. Sponga, E. Ivanitskaia, E. Potapov, T. Krabatsch, R. Hetzer, H. Lehmkuhl, Preoperative treatment with levosimendan in candidates for mechanical circulatory support, ASAIO J. 58 (2012) 6-11.
49. H.D. Theiss, U. Grabmaier, N. Kreissl, et al., Preconditioning with levosimendan before implantation of left ventricular assist devices, Artif. Organs 38 (2014) 231-234.
50. C. Labriola, M. Siro-Brigiani, F. Carrata, E. Santangelo, B. Amantea, Hemodynamic effects of levosimendan in patientswith low-output heart failure after cardiac surgery, Int. J. Clin. Pharmacol. Ther. 42 (2004) 204-211.
51. G. de Lissovoy, K. Fraeman, J.R. Teerlink, J. Mullahy, J. Salon, R. Sterz, A. Durtschi, R.J. Padley, Hospital costs for treatment of acute heart failure: Economic analysis of the REVIVE II study, Eur. J. Health Econ. 11 (2) (2010) 185-193.
52. J.G. Cleland, A. Takala, M. Apajasalo, N. Zethraeus, G. Kobelt, Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: An analysis based on the international LIDO trial, Eur. J. Heart Fail. 5 (1) (2003) 101-108.
53. C. Lucioni, A. D'Ambrosi, S. Mazzi, P. Pollesello, M. Apajasalo, F. Fedele, Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy, Adv. Ther. 29 (12) (2012) 1037-1050.
54. A. Akgul, L. Mavioglu, S.F. Katircioglu, M. Pac, A. Cobanoglu, Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting, Heart Lung Circ. 15 (2006) 320-324.
55. C. Eris, S. Yavuz, F. Toktas, et al., Preoperative usages of levosimendan in patients undergoing coronary artery bypass grafting (CABG, LVEF b 30%), Int. J. Clin. Exp. Med. 7 (2014) 219-229.
56. O.F. Dogan, Levosimendan use decreases atrial fibrillation in patients after coronary artery bypass grafting: A pilot study, Heart Surg. Forum 16 (2013) E287-E294.
57. N. Nijhawan, A.C. Nicolosi, M.W. Montgomery, A. Aggarwal, P.S. Pagel, D.C.Warltier, Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized, placebo-controlled trial, J. Cardiovasc. Pharmacol. 34 (1999) 219-228.
58. J. Alvarez, M. Taboada, J. Rodríguez, et al., Hemodynamic effects of levosimendan following cardiac surgery, Rev. Esp. Anestesiol. Reanim. 52 (2005) 389-394.
59. J. Alvarez, M. Bouzada, A.L. Fernández, et al., Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery, Rev. Esp. Cardiol. (Engl. Ed.) 59 (2006) 338-345.
60. E. Al-Shawaf, A. Ayed, I. Vislocky, B. Radomir, N. Dehrab, R. Tarazi, Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery, J. Cardiothorac. Vasc. Anesth. 20 (2006) 353-357.
61. V.V. Lomivorotov, A.M. Cherniavskiy, V.A. Boboshko, I.A. Kornilov, V.N. Lomivorotov, A.M. Karaskov, Levosimendan vs. intra-aortic balloon pump in high-risk cardiac surgery, Asian Cardiovasc. Thorac. Ann. 19 (2011) 154-159.
62. V.V. Lomivorotov, V.A. Boboshko, S.M. Efremov, et al., Levosimendan versus an intraaortic balloon pump in high-risk cardiac patients, J. Cardiothorac. Vasc. Anesth. 26 (2012) 596-603.
63. A. Tasouli, K. Papadopoulos, T. Antoniou, et al., Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: Importance of early use, Eur. J. Cardiothorac. Surg. 32 (2007) 629-633.
64. A. Ristikankare, R. Pöyhiä, H. Eriksson, M. Valtonen, K. Leino, M. Salmenperä, Effects of levosimendan on renal function in patients undergoing coronary artery surgery, J. Cardiothorac. Vasc. Anesth. 26 (2012) 591-595.
65. W. Toller, L. Algotsson, F. Guarracino, et al., Perioperative use of levosimendan: best practice in operative settings, J. Cardiothorac. Vasc. Anesth. 27 (2013) 361-366.
66. A. Zangrillo, G. Biondi-Zoccai, A.Mizzi, et al., Levosimendan reduces cardiac troponin release after cardiac surgery: A meta-analysis of randomized controlled studies, J. Cardiothorac. Vasc. Anesth. 23 (2009) 474-478.
67. G. Landoni, A. Mizzi, G. Biondi-Zoccai, et al., Reducing mortality in cardiac surgery with levosimendan: Ameta-analysis of randomized controlled trials, J. Cardiothorac. Vasc. Anesth. 24 (2010) 51-57.
68. R. Maharaj, V.Metaxa, Levosimendan and mortality after coronary revascularisation: A meta-analysis of randomised controlled trials, Crit. Care 15 (2011) R140.
69. Z.Z. Niu, S.M. Wu, W.Y. Sun, W.M. Hou, Y.F. Chi, Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: A meta-analysis, J. Cardiovasc. Pharmacol. 63 (2014) 107-112.
70. T. Greco, M.G. Calabrò, R.D. Covello, M. Greco, L. Pasin, A. Morelli, G. Landoni, A. Zangrillo, A Bayesian network meta-analysis on the effect of inodilatory agents on mortality, Br. J. Anaesth. (2015) ( [ePub Feb 4] pii: Aeu446; PMID:25652947).
71. D.Moher, A. Liberati, J. Tetzlaff, D.G. Altman, The PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, PLoS Med. 6 (2008) e1000097.